Accessibility Menu
InnoCare Pharma logo

InnoCare Pharma(SEHK) 9969

Market CapHK$25.92BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)+50%
5 Year-36%
1 Year-16%
1 Month+5%
HK$14.27
-2.73%
-0.40Today
InnoCare Pharma last closing stock price
MetricPriceDate
Last closeHKD 14.272026-08-31
InnoCare Pharma stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.48%HKD 13.792026-08-24
1 month+4.62%HKD 13.642026-07-31
3 month+26.73%HKD 11.262026-06-02
Year to date+16.02%HKD 12.302025-12-31
1 year-15.56%HKD 16.902025-08-29
3 year+114.91%HKD 6.642023-08-31
5 year-35.72%HKD 22.202021-09-01
Since inception+49.54%HKD 9.812020-03-23

InnoCare Pharma Financials at a Glance

Market Cap

HK$25.92BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥2.75B

Net Income (TTM)

CN¥907.26M

EPS (TTM)

HK$0.58

P/E Ratio

25.37

Dividend

HK$0.00

Beta (Volatility)

-0.08 (Low)

Price

HK$14.27

Volume

9,749,185

Open

HK$14.67

Previous Close

HK$14.67

Daily Range

HK$14.00 - HK$14.85

52-Week Range

HK$9.65 - HK$20.18

Estimated Earnings Date

Nov 16, 2026

9969 News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About InnoCare Pharma

InnoCare Pharma Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapeutic agents for oncological and autoimmune disorders. The company is recognized for its lead product, Orelabrutinib, a BTK inhibitor that addresses various forms of lymphomas and autoimmune conditions.

Products and Services
  • Orelabrutinib, a BTK inhibitor for multiple lymphomas
  • ICP-192, a pan-FGFR inhibitor in clinical trials for solid tumors
  • ICP-723, a pan-TRK inhibitor for neurotrophic tyrosine receptor kinase fusion cancers
Growth Outlook
  • Strong pipeline with multiple candidates in various clinical trial phases
  • Recent quarterly revenue of CNY 523.85 million indicates robust market demand
  • TTM gross profit margin of 90.36% reflects operational efficiency
Financial Highlights
  • Net income for Q1 2026 reached CNY 104.86 million
  • Current ratio of 5.65 suggests strong liquidity position
  • TTM return on equity stands at 10.12%, indicating effective capital utilization
InnoCare Pharma Limited, established in 2015 and headquartered in Beijing, China, has positioned itself as a key player in the biotechnology sector. The company’s innovative approach to drug development, particularly in addressing unmet medical needs in oncology and autoimmune diseases, has garnered significant attention. With a strong financial foundation and a promising pipeline, InnoCare is well-equipped to navigate the evolving landscape of biopharmaceuticals. The recent financial performance underscores the company's potential for sustained growth and profitability, making it an intriguing option for investors interested in the healthcare sector.
AI Generated • Aug 23, 2026

Industry

Biotechnology

Sector

Health Care

Employees

1,259

CEO

Jisong Cui, PhD

Website

www.innocarepharma.com

Headquarters

Beijing, BE 102206, CN

9969 Financials

Key Financial Metrics (TTM)

Gross Margin

89.85%

Operating Margin

25.90%

Net Income Margin

32.94%

Return on Equity

12.35%

Return on Capital

4.72%

Return on Assets

8.09%

Earnings Yield

3.94%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

HK$25.92BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.77B

Volume

9.75M

Avg. Volume

8.89M

Financials (TTM)

Gross Profit

CN¥2.48B

Operating Income

CN¥713.27M

EBITDA

CN¥862.74M

Operating Cash Flow

CN¥320.62M

Capital Expenditure

-CN¥84.60M

Free Cash Flow

CN¥236.02M

Cash & ST Invst.

CN¥8.37B

Total Debt

CN¥2.23B

InnoCare Pharma Performance Analysis

InnoCare Pharma annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 722,475,424-42.5%
20232023-12-31CNY 809,708,87612.1%
20242024-12-31CNY 1,083,259,88333.8%
20252025-12-31CNY 2,557,895,103136.1%
InnoCare Pharma sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-309.6%
Q42025-12-31223.4%
Q12026-03-31-57.8%
Q22026-06-3015.7%
InnoCare Pharma annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY -0.581225.2%
20232023-12-31CNY -0.40-32.3%
20242024-12-31CNY -0.27-31.5%
20252025-12-31CNY 0.40N/A
InnoCare Pharma sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3050.8%
Q42025-12-312151.3%
Q12026-03-31-85.1%
Q22026-06-3033.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥605.84M

+73.0%

Gross Profit

CN¥526.73M

+70.2%

Gross Margin

86.94%

N/A

Market Cap

HK$25.92BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

HK$20.58M

N/A

Employees

1,259

N/A

Net Income

CN¥139.94M

+391.2%

EBITDA

CN¥102.72M

+215.8%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥8.37B

+15.5%

Total Debt

CN¥2.23B

+82.1%

Accounts Receivable

CN¥563.41M

+43.6%

Inventory

CN¥198.50M

+68.6%

Long Term Debt

CN¥992.90M

-27.2%

Short Term Debt

CN¥1.24B

+611.1%

Return on Assets

8.09%

N/A

Return on Invested Capital

7.90%

N/A

Free Cash Flow

CN¥77.84M

+160.7%

Operating Cash Flow

CN¥97.24M

+182.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About 9969

What is the current price of InnoCare Pharma?

InnoCare Pharma is trading at HK$14.27 per share.

What is the 52-week range for InnoCare Pharma?

Over the past 52 weeks, InnoCare Pharma has traded between HK$9.65 and HK$20.18.

How much debt does InnoCare Pharma have?

As of the most recent reporting period, InnoCare Pharma reported total debt of CN¥2.58B.

How much cash does InnoCare Pharma have on hand?

InnoCare Pharma reported CN¥7.31B in cash and cash equivalents in its most recent financial results.

What is InnoCare Pharma’s dividend yield?

InnoCare Pharma does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services